Xena Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.50 M
as on 24-10-2024
- Company Age 5 Year, 16 Days
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -54.76%
(FY 2023)
- Ebitda -58.17%
(FY 2023)
- Net Worth -7.01%
(FY 2023)
- Total Assets -0.90%
(FY 2023)
About Xena Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Bipin Pandey and Ritesh Sohgaura serve as directors at the Company.
- CIN/LLPIN
U24230MP2019PTC050369
- Company No.
050369
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Dec 2019
- Date of AGM
31 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Xena Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bipin Pandey  | Director | 16-Dec-2019 | Current |
| Ritesh Sohgaura | Director | 16-Dec-2019 | Current |
Financial Performance of Xena Formulations.
Xena Formulations Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 54.76% decrease in profit. The company's net worth dipped by a decrease of 7.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xena Formulations?
In 2023, Xena Formulations had a promoter holding of 78.00% and a public holding of 22.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Xena Coronus Health Care Private LimitedActive 13 years 11 monthsBipin Pandey and Ritesh Sohgaura are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xena Formulations?
Unlock and access historical data on people associated with Xena Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xena Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xena Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
